UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

The brain is the most complex and least understood organ in the body. NanoSomiX, Inc. is at the forefront in establishing an entirely new class of non-invasive testing to address the need for improved brain analytic tools for research and clinical applications using Brain Derived Exosomes (BDE). They are interested in working collaboratively with researchers worldwide to use their blood-based assay technology to further biomarker exploration in neurodegenerative diseases.

Part of Founders Combined Charity Income Common Investment Fund, Fondazione Telethon is an Italian company located in Rome that operates as a healthcare charity.\nThe company says this about itself: Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than �� 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments.

USAMRMC

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

AFFiRiS AG develops and produces vaccines for therapeutic treatment of chronic diseases. It provides research services and develops vaccines based on peptide antigens applied in the fields of biochemistry, molecular and cell biology, immunology and veterinary medicine. AFFiRiS was founded by Walter Schmidt and Frank Mattner in November 2003 and is headquartered in Vienna, Austria.

Nanjing Drum Tower Hospital is a private company headquartered in China. The firm provides medical services.

Guoke Teshan (Jiangsu) Biotechnology Co., Ltd., established on 2020-09-08, Business scope includes licensed projects:food business;food production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Research and development of biopesticide technology;Biochemical product technology research and development;Primary processing of edible agricultural products;vegetable planting;vegetable,Planting of edible fungi and other horticultural crops;bean planting;Aquatic planting;packaging service;Computer System Services;Data processing and storage support services;data processing services;Artificial intelligence application software development;Artificial intelligence basic software development;AI Hardware Sales;software development;marketing planning;Consulting and planning service;Advertising Design,acting;Health Consulting Services(Does not include medical services);Agricultural Science Research and Experimental Development;Medical Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Biogen International Neuroscience GmbH, part of Biogen, Inc., is a Swiss company located in Schlieren that manufactures biopharmaceutical products. Biogen, Inc. acquired Biogen International Neuroscience GmbH from Neurimmune Holding AG on December 17, 2010 for $427.50 million.

NoNO, Inc. operates as a biotherapeutics company. It engages in the research, development, and commercialization of pharmaceuticals for the treatment of common health disorders that include strokes, traumatic brain injuries, and pains. The company was founded by Michael Tymianski and Michael W. Salter in 2003 and is headquartered in Toronto, Canada.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

BIORCHESTRA is a biotech company that develops RNA-based therapeutics for treating neuroinflammatory diseases. They focus on changing the therapeutic paradigm from treating the symptoms to providing a fundamental cure for diseases. BIORCHESTRA develops neuroinflammatory disease therapeutics, with a particular emphasis on comprehensive patient care. BIORCHESTRA's complementary discovery platforms range from diagnosis to treatment monitoring.

Nanjing Gulou Hospital is a Chinese private company located in Nanjing. The firm operates as a hospital.